ArticleJournal for immunotherapy of cancer2026

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

Aung Naing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.